Mehjabein Khan, MD
Rheumatology · Kenosha, WINPI 1477500312
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,215, 8.6 times the $141 reported in 2022.
Across 161 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$623
- Amgen$478
- AstraZeneca$314
- GSK$265
- UCB, Inc.$243
- Johnson & Johnson$179
- plus $1K from 14 others
What the payments were for
- Consulting fees$903%
- Food & beverage$3,04295%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $623 |
| Amgen | 26 | $478 |
| AstraZeneca(2 entities) | 15 | $314 |
| GSK | 11 | $265 |
| UCB, Inc. | 12 | $243 |
| Johnson & Johnson | 6 | $179 |
| Boehringer Ingelheim | 5 | $130 |
| ANI Pharmaceuticals, Inc. | 4 | $112 |
| Novartis | 5 | $111 |
| Pfizer | 6 | $111 |
| Sandoz | 5 | $109 |
| Mallinckrodt Hospital Products Inc. | 4 | $97 |
| Biocon Biologics Inc | 4 | $92 |
| Lilly USA, LLC | 5 | $89 |
| E.r. Squibb & Sons, L.L.C. | 4 | $87 |
| Sanofi | 2 | $59 |
| Aurinia Pharma U.S., Inc. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $19 |
How this compares
$3,212 in reported general payments places this provider in the 75th percentile of 120 rheumatology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 88 | $819,045 |
| RinvoqUpadacitinib | 65 | $423,066 |
| Enbrel SureclickEtanercept | 52 | $378,224 |
| Humira PenAdalimumab | 17 | $225,761 |
| XeljanzTofacitinib Citrate | 28 | $193,556 |
| Orencia ClickjectAbatacept | 33 | $186,716 |
| Actemra ActpenTocilizumab | 20 | $118,841 |
| Hydroxychloroquine Sulfate | 361 | $15,863 |
| MethotrexateMethotrexate Sodium | 309 | $6,786 |
| Leflunomide | 119 | $5,595 |
| Sulfasalazine | 114 | $4,707 |
| Tizanidine Hcl | 246 | $3,435 |
| Cevimeline Hcl | 20 | $3,309 |
| Colchicine | 26 | $3,126 |
| Pilocarpine Hcl | 44 | $2,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $623 | $423,06665 claims |
| PfizerXeljanz | $111 | $193,55628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 120 rheumatology providers in Wisconsin.
Other rheumatology in Kenosha
- Kurt OelkeGlendale$750K
- Daniel MaloneBeaver Dam$505K
- John AlbertGlendale$369K
- Taraneh MehraniMenomonee Falls$176K
- Ekaterina SoforoSheboygan$159K
- Shikha SinglaMilwaukee$108K
- Eric AndersonOconomowoc$103K
- Isabelle AmiguesGreen Bay$80K
- Sara McCoyMadison$80K
- Mark PearsonBrookfield$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.